Savient Pharmaceuticals Announces Formation of Office of the President

    Savient Pharmaceuticals Announces Formation of Office of the President

PR Newswire

BRIDGEWATER, N.J., June 20, 2013

BRIDGEWATER, N.J., June 20, 2013 /PRNewswire/ -- Savient Pharmaceuticals, Inc.
(NASDAQ: SVNT) announced today that it has formed an Office of the President,
consisting of Richard Crowley, who will serve as Co-President and Chief
Operating Officer, John P. Hamill, who will serve as Co-President and Chief
Financial Officer, and Philip K. Yachmetz, who will serve as Co-President and
Chief Business Officer. Savient also announced that Louis Ferrari, President,
Chief Executive Officer, and Director, is leaving the Company to pursue other
interests, effective immediately, and the Office of the President will succeed
Mr. Ferrari in his executive role.

The Board of Directors thanks Mr. Ferrari for his valuable contributions to
the Company throughout his tenure and wishes him well in his future endeavors.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused
on developing and commercializing KRYSTEXXA^® (pegloticase) for the treatment
of chronic gout in adult patients who do not respond to conventional therapy.
Savient has exclusively licensed worldwide rights to the technology related to
KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View
Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme
and MVP developed the PEGylation technology used in the manufacture of
KRYSTEXXA. MVP and Duke have been granted US and foreign patents disclosing
and claiming the licensed technology and, in addition, Savient owns or co-owns
US and foreign patents and patent applications, which collectively form a
broad portfolio of patents covering the composition, manufacture and methods
of use and administration of KRYSTEXXA. Savient also supplies Oxandrin^®
(oxandrolone tablets, USP) CIII in the US. For more information, please visit
the Company's website at www.savient.com.

SVNT–G

CONTACT:

Savient Pharmaceuticals, Inc.
John P. Hamill
Co-President and Chief Financial Officer
information@savient.com
(732) 418-9300

Burns McClellan
Caitlyn E. Murphy
cmurphy@burnsmc.com
(212) 213-0006

SOURCE Savient Pharmaceuticals, Inc.

Website: http://www.savient.com
 
Press spacebar to pause and continue. Press esc to stop.